FDA
FDA Articles
As we have said before, updates from the FDA have the potential to make or break a company. In this case it seems like a mild setback, but further complications could prove to be catastrophic.
Published:
Last Updated:
BioCryst Pharmaceuticals has received an update from the FDA. This approval is very welcome as BioCryst has been underperforming the market so far this year.
Published:
Last Updated:
Shares of Pluristem Therapeutics saw a handy gain early Monday after the company said it had received a key update from the FDA.
Published:
Last Updated:
Celgene received an update from the FDA early on Thursday. Although shares did not dip initially, this action could prove to be problematic for the biotech giant going forward.
Published:
Last Updated:
Insmed has filed with the SEC for a secondary offering. This follows a surge in the share price following positive late-stage results from its clinical study in the treatment of nontuberculous...
Published:
Last Updated:
Cellectis shares tumbled early on Tuesday after the firm announced that a couple of its early-stage studies were put on hold by the FDA.
Published:
Last Updated:
BioCryst Pharmaceuticals saw its shares make a handy gain on early Tuesday after it released the final results from its mid-stage clinical trial in hereditary angioedema.
Published:
Last Updated:
SteadyMed shares plummeted after the firm had a setback from the FDA regarding its pulmonary arterial hypertension treatment.
Published:
Last Updated:
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and Drug Administration (FDA) approval for its gout treatment...
Published:
Last Updated:
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) saw its shares make a handy gain on Thursday after the company provided an update from the U.S. Food and Drug Administration (FDA)....
Published:
Last Updated:
Here are four biotech stocks for which the team of analysts at Jefferies, and analysts at other firms, see big upside potential from upcoming near-term drug study catalysts.
Published:
Last Updated:
A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its approval of Imbruvica for the treatment of adult patients with chronic graft versus host disease.
Published:
Last Updated:
Gilead Sciences, Inc. (NASDAQ: GILD) shares basically remained unchanged after the firm announced an approval from the U.S. Food and Drug Administration (FDA). Essentially, the FDA approved Vosevi...
Published:
Last Updated:
Puma Biotechnology, Inc. (NASDAQ: PBYI) saw its shares touch a multiyear high on Tuesday after the firm reported a key approval by the U.S. Food and Drug Administration (FDA). Specifically, the...
Published:
Last Updated:
Ocular Therapeutix shares were absolutely crushed on Wednesday after the company received less than favorable news from the FDA regarding its Dextenza in the treatment of ocular pain following...
Published:
Last Updated: